MultiFinder®: Multiplex PCR Technology Based on DNA Fragment Size Analysis


The MultiFinder® technology is PathoFinder's first generation of multiplex PCR technology. The MultiFinder® technology enables the detection and differentiation of up to 22 viral or bacterial targets in a single molecular diagnostic assay.

The MultiFinder® technology uses target specific probes, which, after a ligation step, are amplified and detected by size fractionation. The pathogen identification is based on size fractionation by capillary electrophoresis of the different ligated amplified probes. This reaction is preceded by a target specific amplification to ensure high specificity and sensitivity.



Despite the developments in conventional PCR, the complexity of multiplex PCR is still limited. The MultiFinder® technology is PathoFinder’s proprietary multiplex  PCR technology enabling the detection and differentiation of up to 22 pathogenic (RNA and DNA) targets in a single molecular diagnostic assay by means of size fractionation.

After a gene-specific multiplex reverse transcription step, two unique probes hybridize specifically to the DNA of each pathogen present in the clinical specimen. Hybridized probes are joined by a ligation step and subsequently amplified using a single PCR primer pair for all targets, of which one primer is labelled with a fluorescent dye (FAM/Cy5).

The total length of an amplified probe is unique and specific for a particular  pathogen and can be detected by size fractionation. An Internal Amplification  Control (IAC), which is added at the start of the procedure, is included in the assay to validate a negative sample result.

RespiFinder® 22

50 Assays Cat. No. PF 0500-M


In the attachments below you will find several scientific publications about our technologies and products.

A schematic overview of the MultiFinder technology 107.99